Schedule Update - effective 1 August 2008 (text extract)

This is the text extract for Schedule Update - effective 1 August 2008, browse documents here.

Pharmaceutical Management Agency

Update

New Zealand Pharmaceutical Schedule

Effective 1 August 2008 Cumulative for May, June, July and August 2008 Section H for August 2008

Contents

Summary of PHARMAC decisions effective 1 August 2008 ............................ 3 Levetiracetam – New Antiepilepsy Treatment ................................................ 4 Aripiprazole – New Antipsychotic Treatment ................................................. 5 Glyceryl Trinitrate .......................................................................................... 5 Tender News .................................................................................................. 6 Looking Forward ........................................................................................... 6 Sole Subsidised Supply products cumulative to August 2008 ....................... 8 New Listings ................................................................................................ 14 Changes to Restrictions ............................................................................... 18 Changes to Subsidy and Manufacturer’s Price............................................. 25 Changes to General Rules............................................................................ 31 Changes to PSO........................................................................................... 32 Changes to Sole Subsidised Supply ............................................................. 32 Delisted Items ............................................................................................. 33 Items to be Delisted .................................................................................... 36 Section H changes to Part II ........................................................................ 39 Index ........................................................................................................... 40

Summary of PharmaC decisions

effeCtIve 1 auguSt 2008 New listings (page 14) • Ketoconazole (Sebizole) shampoo 2% 100 ml OP – maximum of 100 ml per prescription, only on a prescription • Condoms 49 mm 144 pack (Marquis Tantaliza), 52 mm 144 pack (Marquis Selecta and Marquis Sensolite), 53 mm 144 pack (Marquis Titillata and Marquis Black), 55 mm 144 pack, (Marquis Conforma), 60 mm 144 pack (Shield XL) – Available on a PSO • Adalimumab (HumiraPen) inj 40 mg per 0.8 ml prefilled pen – Special Authority for subsidy • Levetiracetam (Keppra) – Subsidy by application to a Levetiracetam Special Access Panel • Aripiprazole (Abilify) tab 10 mg, 15 mg, 20 mg and 30 mg – Special Authority for subsidy • Paclitaxel inj 30 mg, 100 mg and 600 mg Changes to restriction (page 18) • Lycinate (glyceryl trinitrate) tab 600 µg – addition of S29 Decreased subsidy (page 25) • Cefuroxime sodium (Mayne) inj 750 mg and 1.5 g • Paclitaxel (Paclitaxel Ebewe) inj 150 mg and 300 mg Increased subsidy (page 25) • Interferon beta-1-beta (Betaferon) inj 8 million iu per ml

4 Pharmaceutical Schedule - Update News

Levetiracetam – New Antiepilepsy Treatment

The Keppra brand of the antiepilepsy agent levetiracetam will be subsidised ‘cost brand source’ for selected patients via a special access process from 1 August 2008. Cost brand source means that there is no set manufacturer’s price in the Schedule and the product will be subsidised at the price it is obtained by the pharmacy. Clinicians will be able to apply for Levetiracetam Special Access (LSA) funding for patients who have tried and failed on, or are unable to take, other funded antiepilepsy agents. Applications will need to be made on approved LSA forms, which will be available from 1 August 2008 on PHARMAC’s website: www.pharmac.govt.nz or from the LSA coordinator: (04) 916-7553 or lsacoordinator@pharmac.govt.nz. Patients will need to have their prescriptions filled at a nominated pharmacy. The nominated pharmacy should be contacted for confirmation prior to applications being submitted. Completed application forms should be sent to the LSA coordinator and will be considered by an LSA Panel at the next practical opportunity following receipt

of the application. Notification of the outcome of the application will be sent to the applying clinician. Initial approvals will be valid for 6 months, with renewals of 12 months where the applicant has demonstrated a clinical need for continued treatment with levetiracetam. LSA funding will be approved for the Keppra brand of levetiracetam only. PHARMAC has not entered into a listing contract with the supplier of Keppra. Therefore, for approved applications there is no surety of source of, or ongoing supply of, Keppra. Approved applications will remain valid until expiry or until such time as an agreed ongoing supply of levetiracetam is available through the Pharmaceutical Schedule. After that time, neither new approvals nor renewals will be given. In order to continue to receive subsidised levetiracetam, patients with existing approvals would need to use a Pharmaceutical Schedule listed brand. Any applicant who considered that their patient should remain on the Keppra brand (if it is not listed in the Schedule) would need to apply in writing outlining the reasons why. At a minimum, patients would need to have been seizure free for at least 6 months for ongoing Keppra subsidy to be considered.

Pharmaceutical Schedule - Update News

Aripiprazole – New Antipsychotic Treatment

Aripiprazole (Abilify) tablets will be listed in the Pharmaceutical Schedule from 1 August 2008. Aripiprazole will be fully subsidised for patients who have previously tried risperidone or quetiapine but had to stop therapy with these medicines because of unacceptable side effects or inadequate response. Clinicians will need to make Special Authority applications for subsidy. See page 14 of this Update for full details.

Glyceryl Trinitrate

Glyceryl trinitrate (Lycinate) tablets are currently supplied under Section 29 of the Medicines Act 1981. Lycinate is currently undergoing registration changes at Medsafe and the Section 29 status will be removed once appropriate changes have been approved by Medsafe. The sole supply status date for Lycinate will be delayed until such registration approval has been granted.

tender News

Sole Subsidised Supply changes – effective 1 September 2008

Chemical Name Aciclovir Aspirin Morphine sulphate Timolol maleate Presentation; Pack size Tab dispersible 200 mg; 25 tab Tab dispersible 400 mg; 56 tab Tab dispersible 300 mg; 100 tab Inj 10 mg per ml, 1 ml; 5 inj Inj 30 mg per ml, 1 ml; 5 inj Eye drops 0.25%; 5 ml OP Eye drops 0.5%; 5 ml OP Sole Subsidised Supply brand (and supplier) Lovir (Douglas) Lovir (Douglas) Ethics Aspirin (Multichem) Mayne (Hospira) Mayne (Hospira) Apo-Timop Apo-Timop

Looking forward

This section is designed to alert both pharmacists and prescribers to possible future changes. It may assist pharmacists to manage stock levels and keep prescribers up-to-date with proposals to change the Pharmaceutical Schedule. Possible decisions for implementation 1 September 2008 • Acarbose (Glucobay) tab 50 mg and 100 mg – amended Special Authority criteria • Acipimox (Olbetam) cap 250 mg – removal of ‘Retail pharmacy – specialist’ • Amiloride (Biomed) oral liq 1 mg per ml – removal of ‘Retail pharmacy – specialist. Specialist must be a paediatrician or paediatric cardiologist.’ • Apo-Clopidogrel (clopidogrel) tab 75 mg – new listing under existing Special Authority criteria • Calcium polystyrene sulphonate powder (Calcium Resonium) – removal of ‘Retail pharmacy – specialist’ • Candesartan (Atacand) – amended Special Authority criteria • Chlorothiazide (Biomed) oral liq 50 mg per ml – removal of ‘Retail pharmacy – specialist. Specialist must be a paediatrician or paediatric cardiologist’ • Dipyridamole tab 25 mg (Persantin) and tab long-acting 150 mg (Pytazen SR) – amended Special Authority criteria • Erythropoietin alpha (Eprex) – new Special Authority criteria • Erythropoietin alpha (Eprex) pre-filled syringe, 1,000 u, 2,000 u, 3,000 u, 4,000 u, 10,000 u – price and subsidy decrease • Erythropoietin alpha (Eprex) pre-filled syringe 5,000 u and 6,000 u – new listing under the new Special Authority criteria

Possible decisions for implementation 1 September 2008 (continued) • Erythropoietin beta (Recormon) - amended Special Authority criteria • Folic acid oral liq 50 µg per ml (Biomed) – removal of ‘Retail pharmacy – specialist. Specialist must be a paedatrician or paediatric cardiologist’ • Frusemide infusion 10 mg per ml, 25 ml (Lasix) and tab 500 mg (Diurin 500) – removal of ‘Retail pharmacy – specialist’ • Heparin sodium inj 25,000 iu per ml, 0.2 ml (Mayne) – removal of ‘Hospital pharmacy [HP3] – specialist’ and increased subsidy • Heparin sodium injection 5,000 iu per 5 ml (Multiparin) – increased subsidy • Imiquimod 5% cream (Aldara) – new listing with Special Authority criteria • Insulin glargine prefilled disposable pen (Lantus SoloStar) – new listing under existing Special Authority criteria • Lithium carbonate (Priadel) tab long-acting – price and subsidy increase • Methylphenidate (Concerta) extended-release tablet 18 mg, 27 mg, 36 mg and 54 mg – new listing with new Special Authority criteria • Midodrine (Gutron) – amended Special Authority criteria • Nicotine (Habitrol) lozenge 1 mg and 2 mg - only on a Quitcard • Nitrofurantoin (Nifuran) tab 50 mg and 100 mg – price and subsidy increase • Plavix (clopidogrel) tab 75 mg – subsidy decrease • Potassium bicarbonate (Phosphate-Sandoz) tab eff 315 mg with sodium acid phosphate 1.937 g and sodium bicarbonate 350 mg – removal of ‘Retail pharmacy – specialist’ • Pravastin (Pravachol) – amended Special Authority criteria • Risperidone (Risperdal) tab 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg – price and subsidy decrease • Risperidone tablets (Ridal, Risperdal) and oral liquid (Risperdal) – removal of ‘Retail pharmacy – Specialist’ • Risperidone microspheres for injection (Risperdal Consta) – amendment of Special Authority criteria • Risperidone orally disintegrating tablets (Risperdal Quicklets) – amendment of Special Authority criteria • Sodium polystyrene powder (Resonium-A) – removal of ‘Retail pharmacy – specialist’ • Spironolactone (Biomed) oral liq 5 mg per ml – removal of ‘Retail pharmacy – specialist. Specialist must be a paediatrician or paediatric cardiologist.’ • Topiramate (Topamax) tab 25 mg, 50 mg, 100 mg, 200 mg, sprinkle cap 15 mg and 25 mg – price and subsidy decrease and removal of Special Authority criteria

Sole Subsidised Supply Products – cumulative to August 2008

Generic Name

Alprazolam

Presentation

Tab 250 µg Tab 500 µg Tab 1 mg Inj 10 mg per ml, 1 ml Cap 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Tab 100 mg Tab 100 mg Tab 50 mg & 100 mg Inj 600 µg, 1 ml Inj 1200 µg, 1 ml Tab 500 mg Metered aqueous nasal spray 50 µg Metered aqueous nasal spray 100 µg Scalp app 0.1% Tab 5 mg Inj 0.5%, 4 ml Inj 0.5%, 8% glucose, 4 ml Lotion BP Crm, aqueous, BP Cap 0.25 µg & 0.5 µg Tab 12.5 mg, 25 mg & 50 mg Cap 250 mg Grans for oral liq 125 mg per 5 ml Crm BP Eye drops 0.5% Eye oint 1% Handrub 1% with ethanol 70% Mouthwash 0.2% Tab 25 mg Tab 250 mg Grans for oral liq 125 mg per 5 ml Crm 0.05% Vaginal crm 1% with applicator(s) Tab 15 mg, 30 mg & 60 mg Tab 500 µg Sach 5 g Inj 150 mg

Brand Name Expiry Date*

Arrow-Alprazolam Arrow-Alprazolam Arrow-Alprazolam Mayne Apo-Amoxi Ranbaxy Amoxicillin Ranbaxy Amoxicillin Apo-Ascorbic Acid Ethics Aspirin EC Loten AstraZeneca AstraZeneca Arrow-Azithromycin Alanase Alanase Beta Scalp Lax-Tab Marcain Isobaric Marcain Heavy ABM ABM Calcitriol-AFT Apo-Captopril Ranbaxy Cefaclor Ranbaxy Cefaclor PSM Chlorsig Chlorsig Orion Orion Hygroton Klamycin Klacid Dermol Clomazol PSM Colgout Colestid Colistin-Link 2010

Apomorphine hydrochloride Amoxycillin

2009 2010 2009 2009 2010 2009 2009 2009 2009 2009 2010 2010 2009 2009 2010 2010 2010 2009 2009 2009 2010 2009 2010 2010 2010 2010 2010

Ascorbic acid Aspirin Atenolol Atropine sulphate Azithromycin Beclomethasone dipropionate Betamethasone valerate Bisacodyl Bupivicaine hydrochloride Calamine Calcitriol Captopril Cefaclor monohydrate Cetomacrogol Chloramphenicol Chlorhexidine gluconate Chlorthalidone Clarithromycin Clobetasol propionate Clotrimazole Codeine phosphate Colchicine Colestipol hydrochloride Colistin sulphomethate

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 8

Sole Subsidised Supply Products – cumulative to August 2008

Generic Name

Compound electrolytes Cyclizine hydrochloride Cyclophosphamide Cyproterone acetate Dantrolene sodium Desferrioxamine mesylate Dexamethasone sodium phosphate Dexamphetamine sulphate Dextrose Dextrose with electrolytes

Presentation

Powder for soln for oral use Tab 50 mg Tab 50 mg Tab 50 mg Cap 25 mg & 50 mg Inj 500 mg Inj 4 mg per ml, 1 ml Inj 4 mg per ml, 2 ml Tab 5 mg Inj 50%, 10 ml Oral soln with electrolytes

Brand Name Expiry Date*

Enerlyte Nausicalm Cycloblastin Siterone Dantrium Mayne Mayne PSM Biomed Pedialyte – Plain Pedialyte – Bubblegum Pedialyte – Fruit Apo-Diclo Apo-Diclo SR Videx EC Apo-Doxazosin m-Enalapril Mayne Cafergot New Zealand Medical and Scientific Brevinor 21 Brevinor 1/21 Brevinor 1/28 Vepesid Ferodan Staphlex AFT AFT Ultraproct Ultraproct 2009 2010 2009 2010 2009 2010 2009 2009 2010 2009 2010 2011 2010

Dicloflenac sodium Didanosine (DDI) Doxazosin mesylate Enalapril Ergometrine maleate Ergotamine tartrate with caffeine Ethinyloestradiol Ethinyloestradiol with norethisterone

Tab EC 25 mg & 50 mg Tab long-acting 75 mg & 100 mg Cap 125 mg, 200 mg, 250 mg & 400 mg Tab 2 mg & 4 mg Tab 5 mg, 10 mg & 20 mg Inj 500 µg per ml, 1 ml Tab 1 mg with caffeine 100 mg Tab 10 µg Tab 35 µg with norethisterone 500 µg Tab 35 µg with norethisterone 1 mg Tab 35 µg with norethisterone 1 mg and 7 inert tab Cap 50 mg & 100 mg Oral liq 150 mg per 5 ml Cap 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Oint 950 µg, with fluocortolone pivalate 920 µg, and cinchocaine hydrochloride 5 mg per g Suppos 630 µg, with fluocortolone pivalate 610 µg, and cinchocaine hydrochloride 1 mg Eye drops 0.1%

2009 2009 2010 2009 2009 2009 2009 2010

Etoposide Ferrous sulphate Flucloxacillin sodium

Fluocortolone caproate with fluocortolone pivalate and cinchocaine

2010

Fluorometholone

Flucon

2009

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 9

Sole Subsidised Supply Products – cumulative to August 2008

Generic Name

Fluoxetine hydrochloride Folic Acid Fusidic acid Gentamicin sulphate Glyceryl trinitrate Haloperidol

Presentation

Cap 20 mg Tab disp 20 mg, scored Tab 0.8 mg & 5 mg Crm 2% & Oint 2% Inj 40 mg per ml, 2 ml TDDS 5 mg TDDS 10 mg Oral liq 2 mg per ml Tab 500 µg, 1.5 mg & 5 mg Inj 5 mg per ml, 1 ml Inj 10 iu per ml, 5 ml Tab 5 mg & 20 mg Rectal foam 10%, CFC-Free Scalp lotn 0.1% Oral liq 100 mg per 5 ml, 200 ml Tab 10 mg & 25 mg Tab 2.5 mg Aqueous nasal spray, 0.03% Nebuliser soln, 250 µg per ml, 1 ml Nebuliser soln, 250 µg per ml, 2 ml Tab long-acting 60 mg Cap 10 mg Cap 20 mg Cap 100 mg Oral liq 10 g per 15 ml Eye drops 0.25% & 0.5% Cap 50 mg with benserazide 12.5 mg Tab dispersible 50 mg with benserazide 12.5 mg Cap 100 mg with benserazide 25 mg Cap long-acting 100 mg with benserazide 25 mg Cap 200 mg with benserazide 50 mg Inj 0.5%, 5 ml Inj 1%, 5 ml Inj 1%, 20 ml Crm 2.5% with prilocaine 2.5%; 30 g OP Crm 2.5% with prilocaine 2.5%; 5 g Tab 5 mg, 10 mg & 20 mg

Brand Name Expiry Date*

Fluox Fluox Apo-Folic Acid Foban Pfizer Nitroderm TTS 5 Nitroderm TTS 10 Serenace Serenace Serenace AstraZeneca Douglas Colifoam Locoid Fenpaed Tofranil Napamide Apo-Ipravent Ipratripium Steri-Neb Ipratripium Steri-Neb Duride Isotane 10 Isotane 20 Sporanox Duphalac Betagan Madopar 62.5 Madopar Dispersible Madopar 125 Madopar HBS Madopar 250 Xylocaine Xylocaine Xylocaine EMLA EMLA Arrow-Lisinopril 2009 2010 2010 2009 2010 2009 2011 2010 2009 2009 2009 2009 2010 2010 2009 2009 2010

Heparinised saline Hydrocortisone Hydrocortisone acetate Hydrcortisone butyrate Ibuprofen Imipramine hydrochloride Indapamide Ipratropium bromide

Isosorbide mononitrate Isotretinoin Itraconazole Lactulose Levobunolol Levodopa with benserazide

2009 2009 2010 2010 2010 2009

Lignocaine hydrochloride

Lignocaine with prilocaine

2010

Lisinopril

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 10

Sole Subsidised Supply Products – cumulative to August 2008

Generic Name

Loperamide hydrochloride Loratadine

Presentation

Tab 2 mg Tab 10 mg Oral liq 1 mg per ml

Brand Name Expiry Date*

Nodia Loraclear Hayfever Relief Lorapaed Ativan Mayne Derbac M A-Lices Ludiomil Provera Pentasa Arrow-Metformin Methatabs AFT Methoblastin Rubifen SR Rubifen Rubifen Medrol Advantan Solu-Medrol Solu-Medrol Solu-Medrol Slow-Lopresor Metopirone Gutron Cytotec Apo-Moclobemide RA-Morph RA-Morph RA-Morph RA-Morph Mayne Mayne m-Eslon Sevredol Mayne 2009 2010 2010

Lorazepam Magnesium sulphate Malathion Maldison Maprotiline hydrochloride Medroxyprogesterone acetate Mesalazine Metformin hydrochloride Methadone hydrochloride Methotrexate Methylphenidate hydrochloride

Tab 1 mg & 2.5 mg Inj 49.3% Liq 0.5% Shampoo 1% Tab 25 mg & 75 mg Tab 2.5 mg, 5 mg, 10 mg, 100 mg & 200 mg Enema 1 g per 100 ml Tab 500 mg & 850 mg Tab 5 mg Powder 1 g Tab 2.5 mg & 10 mg Tab long-acting 20 mg Tab 5 mg & 20 mg Tab 10 mg Tab 4 mg & 100 mg Crm 0.1% and oint 0.1% Inj 40 mg per ml, 1 ml Inj 62.5 mg per ml, 1 ml Inj 500 mg & 1 g Tab long-acting 200 mg Cap 250 mg Tab 2.5 mg & 5 mg Tab 200 µg Tab 150 mg & 300 mg Oral liq 1 mg per ml Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Inj 5 mg per ml, 1 ml Inj 15 mg per ml, 1 ml Cap long-acting 10 mg, 30 mg, 60 mg, 100 mg & 200 mg Tab immediate release 10 mg & 20 mg Inj 80 mg per ml, 1.5 ml & 5 ml

2009 2009 2010 2010 2009 2010 2009 2009 2010 2009 2009 2009

Methylprednisolone Methylprednisolone aceponate Methylprednisolone sodium succinate Metoprolol tartrate Metyrapone Midodrine Misoprostol Moclobemide Morphine hydrochloride

2009 2009 2009

2009 2009 2009 2009 2009 2009

Morphine sulphate

2009

Morphine tartrate

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 11

Sole Subsidised Supply Products – cumulative to August 2008

Generic Name

Nadolol Naltrexone hydrochloride Naproxen Naproxen sodium Neostigmine Nevirapine Nicotinic acid Nifedipine Norethisterone Nystatin

Presentation

Tab 40 mg & 80 mg Tab 50 mg Tab 250 mg Tab 500 mg Tab 275 mg Inj 2.5 mg per ml, 1 ml Oral suspension 10 mg per ml Tab 50 mg & 500 mg Tab long-acting 20 mg Tab 350 µg Cap 500,000 u Tab 500,000 u Vaginal crm 100,000 u per 5 g with applicators Tab 4 mg & 8 mg Tab disp 4 mg & 8 mg Tab 5 mg Oral liq 5 mg per 5 ml Inj 10 mg per ml, 1 ml and 2 ml Oral liq 5 mg per 5 ml Inj 5 iu per ml, 1 ml Inj 10 iu per ml, 1 ml Inj 5 iu with ergometrine maleate 500 µg per ml, 1 ml Tab 20 mg Tab 40 mg

Brand Name Expiry Date*

Apo-Nadolol ReVia Noflam 250 Noflam 500 Sonaflam AstraZeneca Viramune Suspension Apo-Nicotinic Acid Nyefax Retard Noriday 28 Nilstat Nilstat Nilstat Zofran Zofran Zydis Apo-Oxybutynin Apo-Oxybutynin OxyNorm OxyNorm Syntocinon Syntocinon Syntometrine Dr Reddy’s Pantoprazole Dr Reddy’s Pantoprazole Lacri-Lube Loxamine Pexsig AFT AFT Cilicaine VK Cilicaine VK Prefrin Span-K Apo-Prazo MDS Quick Card Apo-Pyridoxine 2010 2010 2009 2010 2010 2009 2009 2009 2009 2010 2009 2010 2010 2010 2009

Ondansetron Oxybutynin Oxycodone hydrochloride Oxytocin

Pantoprazole

2010

Paraffin liquid with soft white paraffin Paroxetine hydrochloride Perhexiline maleate Phenoxymethylpenicillin (Penicillin V)

Eye oint with soft white paraffin Tab 20 mg Tab 100 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Cap potassium salt 250 mg Cap potassium salt 500 mg Eye drops 0.12% Tab long-acting 600 mg Tab 1 mg, 2 mg & 5 mg Cassette Tab 50 mg

2010 2010 2009 2010

Phenylephrine hydrochloride Potassium chloride Prazosin hydrochloride Pregnancy tests - HCG urine Pyridoxine hydrochloride

2010 2009 2010 2009 2009

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 12

Sole Subsidised Supply Products – cumulative to August 2008

Generic Name

Quinine sulphate Ranitidine hydrochloride Rifabutin Roxithromycin Salbutamol

Presentation

Tab 200 mg Tab 300 mg Oral liq 150 mg per 10 ml Cap 150 mg Tab 150 mg & 300 mg Nebuliser soln 1 mg per ml, 2.5 ml Nebuliser soln 2 mg per ml, 2.5 ml Oral liq 2 mg per 5 ml Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg Tab 5 mg Inj 0.9%, 5 ml & 10 ml Grans eff 4 g sachets Nasal spray 4% Tab 500 mg Tab EC 500 mg Liq Tab 10 mg Tab 50 mg Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g Inj 1 mg per ml, 1 ml Inj 1 mg per ml, 2 ml Tab (BPC cap strength) Tab, strong, BPC Purified for injection 20 ml

Brand Name Expiry Date*

Q 200 Q 300 Peptisoothe Mycobutin Arrow-Roxithromycin Asthalin Asthalin Salapin Duolin Apo-Selegiline AstraZeneca Ural Rex Salazopyrin Salazopyrin EN Midwest Apo-Timol Apo-Thiamine Kenacomb 2009 2010 2010 2009 2009 2010 2009 2009 2009 2010 2009 2009 2010 2009 2009 2009

Salbutamol with ipratropium bromide Selegiline hydrochloride Sodium chloride Sodium citro-tartrate Sodium cromoglycate Sulphasalazine Syrup (pharmaceutical grade) Timolol maleate Thiamine hydrochloride Triamcinolone acetonide with gramicidin, neomycin and nystatin Vincristine sulphate Vitamins Vitamin B complex Water August changes in bold type.

Mayne Mayne Healtheries Apo-B-Complex Multichem

2009 2009 2009 2009

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 13

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings

Effective 1 August 2008

68 KETOCONAZOLE Shampoo 2%............................................................................. 3.48 a) maximum of 100 ml per prescription b) Only on a prescription CONDOMS ❋ 49 mm – Up to 144 dev available on a PSO ............................. 13.36 ❋ 52 mm – Up to 144 dev available on a PSO ............................. 13.36 ❋ 52 mm – Up to 144 dev available on a PSO ............................. 13.36 ❋ 53 mm – Up to 144 dev available on a PSO ............................. 13.36 ❋ 53 mm – Up to 144 dev available on a PSO ............................. 13.36 ❋ 55 mm – Up to 144 dev available on a PSO ............................. 13.36 ❋ 60 mm – Up to 144 dev available on a PSO ............................. 13.36 100 110 115 ADALIMUMAB – Special Authority see SA0812 – Retail Pharmacy Inj 40 mg per 0.8 ml pre-filled pen ...................................... 1,799.92 100 ml OP ✔ Sebizole

144 144 144 144 144 144 144 2

✔ Marquis Tantaliza ✔ Marquis Selecta ✔ Marquis Sensolite ✔ Marquis Titillata ✔ Marquis Black ✔ Marquis Conforma ✔ Shield XL

✔ HumiraPen

LEVETIRACETAM – Subsidy by application to the Levetiracetam Special Access Panel Tab ...................................................................................... CBS 1 ✔ Keppra ARIPIPRAZOLE – Special Authority see SA0920 – Retail Pharmacy Tab 10 mg ............................................................................ 123.54 30 ✔ Abilify Tab 15 mg ............................................................................ 175.28 30 ✔ Abilify Tab 20 mg ............................................................................ 213.42 30 ✔ Abilify Tab 30 mg ............................................................................ 260.07 30 ✔ Abilify ➽ SA0920 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Patient is suffering from schizophrenia or related psychoses; and 2 Either: 2.1 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of unacceptable side effects; or 2.2 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of inadequate clinical response. Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. PACLITAXEL – PCT only – Specialist Inj 30 mg ............................................................................... 37.95 Inj 100 mg ........................................................................... 125.35 Inj 600 mg ............................................................................ 724.50 1 1 1 ✔ Paclitaxel Ebewe ✔ Paclitaxel Ebewe ✔ Paclitaxel Ebewe

131

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings - effective 1 July 2008

27 37 OMEPRAZOLE ❋ Cap 10 mg ............................................................................... 2.14 ❋ Cap 20 mg ............................................................................... 3.05 ❋ Cap 40 mg ............................................................................... 3.59 CALCIUM ❋ Tab eff 1 g................................................................................. 6.54 IRON POLYMALTOSE Inj 50 mg per ml, 2 ml ............................................................ 20.95 GLYCERYL TRINITRATE ❋ Tab 600 µg – Up to 100 tab available on a PSO ........................ 8.00 ZINC AND CASTOR OIL Oint BP...................................................................................... 5.11 PARACETAMOL ❋‡ Oral liq 120 mg per 5 ml ......................................................... 6.80 a) Up to 200 ml available on a PSO b) Not in combination ❋‡ Oral liq 250 mg per 5 ml ......................................................... 7.00 a) Up to 100 ml available on a PSO b) Not in combination 107 147 NORTRIPTYLINE HYDROCHLORIDE Tab 25 mg .............................................................................. 17.45 250 30 30 30 ✔ Dr Reddy’s Omeprazole ✔ Dr Reddy’s Omeprazole ✔ Dr Reddy’s Omeprazole ✔ Calcium Sandoz ✔ Calsource ✔ Ferrum H ✔ Lycinate ✔ PSM ✔ Paracare Junior ✔ Paracare Double Strength

37 60 65 104

5 100 OP 500 g 1,000 ml 1,000 ml

✔ Norpress

BUDESONIDE WITH EFORMOTEROL – Special Authority see SA0838– Retail pharmacy Aerosol inhaler 100 µg with eformoterol fumarate 6 µg ............ 55.00 120 dose OP ✔ Vannair Aerosol inhaler 200 µg with eformoterol fumarate 6 µg ............ 60.00 120 dose OP ✔ Vannair GLUTEN FREE PASTA – Special Authority see SA0722– Hospital pharmacy [HP3] Garlic and Parsley Shells .......................................................... 2.00 250 g OP (2.63)

177

Orgran

Effective 1 June 2008

35 46 HYDROXOCOBALAMIN ❋ Inj 1 mg per ml, 1 ml ................................................................. 9.21 HEPARINISED SALINE ❋ Inj 100 iu per ml, 2 ml ............................................................... 8.30 3 ✔ ABM Hydroxocobalamin ✔ Hospira S29

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings - effective 1 June 2008 (continued)

54 70 LOSARTAN – Special Authority see SA0911 – Retail Pharmacy ❋ Tab 25 mg .............................................................................. 20.31 CONDOMS ❋ 49mm - Up to 144 dev available on a PSO ................................ 1.11 ❋ 49mm - Up to 144 dev available on a PSO ............................... 13.36 ❋ 53mm (chocolate) - Up to 144 dev available on a PSO............. 13.36 ❋ 53mm (strawberry) - Up to 144 dev available on a PSO ........... 13.36 ❋ 55mm - Up to 144 dev available on a PSO ................................. 1.11 ❋ 55mm - Up to 144 dev available on a PSO .............................. 13.36 ❋ 53mm extra strength - Up to 144 dev available on a PSO ........... 1.11 ❋ 53mm extra strength - Up to 144 dev available on a PSO ......... 13.36 LEVONORGESTREL ❋ Tab 1.5 mg ............................................................................ 12.50 a) Maximum of 1 tab per prescription b) Up to 5 tab available on a PSO OESTRADIOL VALERATE ❋ Tab 1 mg .................................................................................. 8.24 LAMOTRIGINE ▲ Tab dispersible 25 mg ............................................................. 19.38 ▲ Tab dispersible 50 mg ............................................................. 32.97 ▲ Tab dispersible 100 mg ........................................................... 56.91 RIZATRIPTAN BENZOATE Wafer 10 mg ........................................................................... 25.32 SALBUTAMOL Aerosol inhaler, 100 µg per dose CFC free – Up to 1000 dose available on a PSO ...................................... 3.80 28 12 144 144 144 12 144 12 144 1 ✔ Cozaar ✔ Gold Knight ✔ Gold Knight ✔ Gold Knight ✔ Gold Knight ✔ Gold Knight ✔ Gold Knight ✔ Gold Knight ✔ Gold Knight

✔ Postinor-1

79 110 112 147

56 56 56 56 3

✔ Progynova

✔ Logem ✔ Logem ✔ Logem ✔ Maxalt Melt

200 dose OP ✔ Respigen

167 168 168

ORAL SUPPLEMENT 1KCAL/ML – Special Authority see SA0583 – Hosptial pharmacy [HP3] Powder (vanilla) sachet 54 g ..................................................... 6.91 10 ✔ Fortisip Powder DIABETIC ENTERAL FEED 1KCAL/ML – Special Authority see SA0594 – Hospital Pharmacy [HP3] Liquid ........................................................................................ 7.50 1000 ml OP ✔ Glucerna Select RTH ORAL FEED 1KCAL / ML – Special Authority see SA0594 – Hospital Pharmacy [HP3] Liquid (vanilla)........................................................................... 1.88 250 ml OP ✔ Glucerna Select

Effective 1 May 2008

31 INSULIN PEN NEEDLES – Maximum of 100 dev per prescription ❋ 29 g x 12.7 mm ...................................................................... 11.75 ❋ 31 g x 6 mm ........................................................................... 11.75 ❋ 31 g x 8 mm ........................................................................... 11.75 100 100 100 ✔ ABM ✔ ABM ✔ ABM

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings - effective 1 May 2008 (continued)

32 INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE – Maximum of 100 dev per prescription ❋ Syringe 0.3 ml with 29 g × 12.7 mm needle ........................... 14.45 100 ✔ ABM ❋ Syringe 0.3 ml with 31 g × 8 mm needle ................................ 14.45 100 ✔ ABM ❋ Syringe 0.5 ml with 29 g × 12.7 mm needle ........................... 14.45 100 ✔ ABM ❋ Syringe 0.5 ml with 31 g × 8 mm needle ................................ 14.45 100 ✔ ABM ❋ Syringe 1 ml with 29 g × 12.7 mm needle .............................. 14.45 100 ✔ ABM ❋ Syringe 1 ml with 31 g × 8 mm needle ................................... 14.45 100 ✔ ABM CONDOMS ❋ 53 mm (chocolate) .................................................................... 1.11 ❋ 53 mm (strawberry) .................................................................. 1.11 VALACICLOVIR Tab 500 mg .......................................................................... 163.80 12 12 30 ✔ Gold Knight ✔ Gold Knight

91 95 108

✔ Valtrex ✔ Norvir ✔ Efexor XR

RITONAVIR – Special Authority see SA0779 on page 93 – Hospital pharmacy [HP1] Cap 100 mg .......................................................................... 121.27 84 VENLAFAXINE – Special Authority see SA0789 below – Retail pharmacy Cap 37.5 mg ........................................................................... 18.64 28

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions

Effective 1 August 2008

60 GLYCERYL TRINITRATE ❋ Tab 600 µg – Up to 100 tab available on a PSO ......................... 8.00 100 OP ✔ Lycinate S29

Effective 1 July 2008

24 BUDESONIDE Cap 3 mg – Special Authority see SA0913 0698 – Retail pharmacy................................................................. 166.50 90 ✔ Entocort CIR ➽ SA0913 0698 Special Authority for Subsidy Initial application only from any relevant practitioner a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months for applications meeting the following criteria: Both: 1. Mild to moderate ileal, ileocaecal or proximal Crohn’s disease; and 2. Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fracture; or 2.4 Severe acne following treatment with conventional corticosteroid therapy. Renewal only from any relevant practitioner a gastroenterologist, general surgeon or general physician. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment. OLSALAZINE – Retail pharmacy-Specialist Tab 500 mg ............................................................................ 59.86 Cap 250 mg ........................................................................... 31.51 SODIUM CROMOGLYCATE Cap 100 mg – Hospital pharmacy [HP3]-Specialist .................. 89.21 MEBEVERINE HYDROCHLORIDE – Retail pharmacy-Specialist ❋ Tab 135 mg ........................................................................... 10.72 (25.73) MISOPROSTOL – Retail pharmacy-Specialist ❋ Tab 200 µg ............................................................................ 52.70 100 100 100 90 Colofac 120 ✔ Cytotec ✔ Dipentum ✔ Dipentum ✔ Nalcrom

25 26 26 26

RANITIDINE HYDROCHLORIDE – Only on a prescription ❋ Oral liq 150 mg per 10 ml – Subsidy by endorsement ................ 7.95 300 ml ✔ Peptisoothe Oral liquid is subsidized for patients: 1. with oesophageal stricture, or 2. in terminal care, or 3. who are either too young or too old to swallow conventional tablets and the prescription is endorsed accordingly Note: the cost of treatment with ranitidine oral liquid is more than 10 times higher than that of ranitidine tablets. Following the derestriction of access PHARMAC will be monitoring expenditure on ranitidine oral liquid more closely and may, subject to consultation and PHARMAC Board approval, restrict access again if expenditure was to grow substantially.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2008 (continued)

32 URSODEOXYCHOLIC ACID – Special Authority see SA0914 0841 Retail pharmacy Cap 300 mg ......................................................................... 269.98 100 ✔ Actigall ➽ SA0914 0841 Special Authority for Subsidy Initial application only from any relevant practitioner a gastroenterologist or general physician. Approvals valid for 6 months for applications meeting the following criteria: Both: 1. Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and 2. Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis). Note: Liver biopsy is not usually required for diagnosis but is helpful to stage the disease. Renewal only from any relevant practitioner a gastroenterologist or general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. Note: Actigall is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centre. Treatment failure – doubling of serum bilirubin levels, absence of a significant decrease in ALP or ALT and AST, development of varices, ascites or encephalopathy, marked worsening of pruritus or fatigue, histological progression by two stages, or to cirrhosis, need for transplantation. 34 BENZYDAMINE HYDROCHLORIDE – Retail pharmacy-Specialist prescription Soln 0.15% ............................................................................... 9.00 500 ml (15.36) ALFACALCIDOL – Retail pharmacy-Specialist Cap 0.25 µg ........................................................................... 26.32 Cap 1 µg ................................................................................ 87.98 Oral drops 2 µg per ml ........................................................... 60.68 100 100 20 ml OP

Difflam ✔ One-Alpha ✔ One-Alpha ✔ One-Alpha

ALPHA TOCOPHERYL ACETATE – Special Authority see SA0915 0264 – Hospital pharmacy [HP3] Water solubilised soln 156 iu/ml, with calibrated dropper ......... 18.30 50 ml OP ✔ Micelle E ➽ SA0915 0264 Special Authority for Subsidy Initial application only from any relevant practitioner a paediatrician or respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1. Cystic fibrosis patient; or Both: 2. Infant or child with liver disease or short gut syndrome; and 3. Requires vitamin supplementation. Renewal only from any relevant practitioner a paediatrician or respiratory specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

36 47 47

CALCITRIOL – Retail pharmacy-Specialist ❋ Cap 0.25 µg ........................................................................... 13.45 ❋ Cap 0.5 µg ............................................................................. 24.95 ❋ Oral liq 1 µg per ml ................................................................. 39.40 CALCIUM POLYSTYRENE SULPHONATE – Retail pharmacy-Specialist Powder ................................................................................. 169.85 SODIUM POLYSTYRENE SULPHONATE – Retail pharmacy-Specialist Powder ................................................................................... 89.10 Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

100 100 10 ml OP 300 g OP 450 g OP

✔ Calcitriol-AFT ✔ Calcitriol-AFT ✔ Rocaltrol solution ✔ Calcium Resonium ✔ Resonium-A

▲

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2008 (continued)

73 LEVONORGESTREL ❋ Tab 1.5 mg ............................................................................ 12.50 a) Maximum of 1 2 tab per prescription b) Up to 5 tab available on a PSO 1 ✔ Postinor-1

117

ZIPRASIDONE Ziprasidone is subsidised for patients suffering from schizophrenia or related psychoses after a trial of an effective dose of risperidone or quetiapine that has been discontinued, or is in the process of being discontinued, because of unacceptable side effects or inadequate response, and the prescription is endorsed accordingly.

Effective 1 June 2008

54 LOSARTAN ➽ SA0862 Special Authority for Subsidy Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Both: 1.1 Patient with congestive heart failure; and 1.2 Either: 1.2.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 1.2.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years; or 2 All of the following: 2.1 Patient with raised blood pressure; and 2.2 Use of fully funded beta blockers or diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 2.3 Either: 2.3.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 2.3.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. ➽ SA0911 Special Authority for Subsidy Initial application – (ACE inhibitor intolerant) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patient has persistent ACE inhibitor induced cough that has recurred by ACE inhibitor retrial (same or new ACE inhibitor); or 2 Patient has a history of angioedema. Initial application - (Unsatisfactory response to ACE inhibitor) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient’s condition is not adequately controlled on maximum tolerated dose of an ACE inhibitor. Initial application (patient has had an approval for losartan with hydrochlorothiazide prior to 1 May 2008) from any relevant practitioner. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment. 54 LOSARTAN WITH HYDROCHLOROTHIAZIDE ➽ SA0862 Special Authority for Subsidy Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Both: continued...

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 June 2008 (continued)

continued... 1.1 Patient with congestive heart failure; and 1.2 Either: 1.2.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 1.2.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years; or 2 All of the following: 2.1 Patient with raised blood pressure; and 2.2 Use of fully funded beta blockers or diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 2.3 Either: 2.3.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 2.3.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. ➽ SA0911 Special Authority for Subsidy Initial application – (ACE inhibitor intolerant) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patient has persistent ACE inhibitor induced cough that has recurred by ACE inhibitor retrial (same or new ACE inhibitor); or 2 Patient has a history of angioedema. Initial application - (Unsatisfactory response to ACE inhibitor) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient’s condition is not adequately controlled on maximum tolerated dose of an ACE inhibitor. Initial application (patient has had an approval for losartan with hydrochlorothiazide prior to 1 May 2008) from any relevant practitioner. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment. 109 GABAPENTIN ➽ SA0873 Special Authority for Subsidy Initial application — (Epilepsy - new patients) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Either: 1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or 2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents. Note: “Optimal treatment with other antiepilepsy agents” is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Initial application — (Epilepsy - patient has had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life from gabapentin, topiramate, vigabatrin and/or lamotrigine. Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. Initial application — (Neuropathic pain - new patients) from any relevant practitioner. Approvals valid for 3 months where the patient has tried and failed, or has been unable to tolerate, treatment with a tricyclic antidepressant AND an anticonvulsant agent. Initial application — (Neuropathic pain - patient has had an approval for gabapentin for neuropathic pain prior to 1 August 2007) from any relevant practitioner. Approvals valid for 2 years where the patient has demonstrated a marked improvement in their control of pain (prescriber determined). continued...

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 June 2008 (continued)

continued... Renewal — (Epilepsy) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life. Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. If the patient had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Renewal — (Neuropathic pain) from any relevant practitioner. Approvals valid for 2 years where the patient has demonstrated a marked improvement in their control of pain (prescriber determined). Note: If the patient had an approval for gabapentin for neuropathic pain prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. 110 TOPIRAMATE ➽ SA0874 Special Authority for Subsidy Initial application — (new patients) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both: 1 Patient has epilepsy; and 2 Either: 2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or 2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents. Note: “Optimal treatment with other antiepilepsy agents” is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Initial application — (patient has had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life life from gabapentin, topiramate, vigabatrin and/or lamotrigine. Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life. Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. If the patient had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. 111 VIGABATRIN ➽ SA0875 Special Authority for Subsidy Initial application — (new patients) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: All of the following: 1 Patient has epilepsy; and 2 Either: 2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or 2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and 3 Either: continued... Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 June 2008 (continued)

continued... 3.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or 3.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient’s visual fields. Notes: “Optimal treatment with other antiepilepsy agents” is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages. Initial application — (patient has had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life from gabapentin, topiramate, vigabatrin and/or lamotrigine; and 2 Either: 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for the duration of treatment with vigabatrin; or 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient’s visual fields. Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages. Renewal from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life; and 2 Either: 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient’s visual fields. Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages. If the patient had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. 164 CARBOHYDRATE ➽ SA0579 SA0912 Special Authority for Subsidy Initial application - (Cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 cystic fibrosis; or 2 chronic renal failure or continuous ambulatory peritoneal dialysis (CAPD) patient. Initial application - (Indications other than cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 cancer in children; or continued...

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 June 2008 (continued)

continued... 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or 3 failure to thrive; or 4 growth deficiency; or 5 bronchopulmonary dysplasia; or 6 premature and post premature infant; or 7 inborn errors of metabolism Renewal - (Cystic fibrosis or renal failure) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted. Renewal - (Indications other than cystic fibrosis or renal failure) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.

Effective 1 May 2008

91 PYRAZINAMIDE – Retail pharmacy-Specialist No patient co-payment payable ❋ Tab 500 mg ........................................................................... 59.00 100 ✔ AFT-Pyrazinamide

S29

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price

Effective 1 August 2008

62 ECONAZOLE NITRATE ( price) Foaming solution 1%, 10 ml sachets.......................................... 9.89 (15.66) CONDOMS ( price) 54 mm shaped – Up to 144 dev available on a PSO ................... 1.11 (1.24) 56 mm, shaped – Up to 144 dev available on a PSO ................ 13.36 1.11 3 Pevaryl Foaming Solution

12 144 12

Lifestyles Flared ✔ Durex Confidence ✔ Durex Confidence

CEFUROXIME SODIUM – Hospital Pharmacy [HP3] ( subsidy) Inj 750 mg – Maximum of 1 inj per prescription; can be waived by endorsement ............................................ 21.42 10 (56.47) Mayne Inj 1.5 g - Hospital Pharmacy [HP3] – Specialist – Subsidy by Endorsement ( subsidy) ................................... 40.40 10 (123.55) Mayne Only if prescribed for a dialysis or cystic fibrosis patient and the prescription is endorsed accordingly. PACLITAXEL - PCT only - Specialist ( subsidy) Inj 150 mg ............................................................................ 188.03 Inj 300mg ............................................................................ 376.05 1 1 ✔ Paclitaxel Ebewe ✔ Paclitaxel Ebewe

131

141 176

INTERFERON BETA-1-BETA - Special Authority see SA0470 – Hospital Pharmacy [HP3] ( subsidy) Inj 8 million iu per 1 ml ........................................................ 1378.71 15 ✔ Betaferon GLUTEN FREE BREAD MIX – Special Authority see SA0722 – Hospital pharmacy [HP3] Powder ..................................................................................... 3.51 1,000 g OP (9.96)

Horleys Bread Mix

176

GLUTEN FREE FLOUR – Special Authority see SA0722 – Hospital pharmacy [HP3] ( price) Powder ..................................................................................... 5.62 2,000 g OP (16.44) Horleys Flour

Effective 1 July 2008

27 OMEPRAZOLE ( subsidy) ❋ Cap 10 mg ................................................................................ 2.14 (5.95) ❋ Cap 20 mg ................................................................................ 3.05 (5.95) ❋ Cap 40 mg ................................................................................ 3.59 (8.84) GLICLAZIDE ( subsidy) ❋ Tab 80 mg .............................................................................. 22.24 30 Omezol 30 Omezol 30 Omezol 500

29 32

✔ Apo-Gliclazide

URSODEOXYCHOLIC ACID – Special Authority see SA0841 – Retail Pharmacy ( subsidy) Cap 300 mg .......................................................................... 179.00 100 ✔ Actigall Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber. ❋ Three months or six months, as applicable, dispensed all-at-once

▲

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price - effective 1 July 2008 (continued)

35 62 TRIAMCINOLONE ACETONIDE ( subsidy) 0.1% in Dental Paste USP .......................................................... 4.38 CLOTRIMAZOLE ( subsidy) ❋ Crm 1% ..................................................................................... 0.50 a) Only on a prescription b) Not in combination MICONAZOLE NITRATE ( subsidy) ❋ Crm 2% ..................................................................................... 0.42 a) Only on a prescription b) Not in combination BETAMETHASONE VALERATE ( subsidy) ❋ Crm 0.1% ................................................................................. 2.00 ❋ Oint 0.1% ................................................................................. 2.20 HYDROCORTISONE ( price) ❋ Crm 1% – Only on a prescription ............................................ 12.20 EMULSIFYING OINTMENT ( subsidy) ❋ Ointment BP .............................................................................. 3.69 5 g OP 20 g OP ✔ Oracort

✔ Clomazol

15 g OP

✔ Multichem

63 64 65 68

50 g OP 50 g OP 500 g

✔ Beta Cream ✔ Beta Ointment

✔ PSM

500 g

✔ AFT

SALICYLIC ACID ( subsidy) Powder – Only in combination ................................................. 15.00 500 g (55.63) David Craig 1) Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain or collodion flexible, 2) With or without other dermatological galenicals 3) Maximum 20 g or 20 ml per prescription when prescribed with white soft paraffin or collodion flexible. SULPHUR ( subsidy) Precipitated – Only in combination ............................................. 6.50 100 g (9.25) PSM 1) Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain, 2) With or without other dermatological galenicals. SUNSCREENS, PROPRIETARY – Subsidy by endorsement ( subsidy) Only if prescribed for a patient with severe phostosensitivity secondary to a defined clinical condition and the prescription is endorsed accordingly Crm........................................................................................... 2.55 100 g OP (5.89) Hamilton Sunscreen 1.28 50 g OP (5.84) Aquasun Oil Free Faces SPF 30+ Lotn .......................................................................................... 3.19 125 ml OP (8.82) Aquasun Sensitive SPF 30+ 125 ml OP (9.38) Aquasun 30+

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price - effective 1 July 2008 (continued)

70 CONDOMS ( subsidy) ❋ 52mm – Up to 144 dev available on a PSO .............................. 13.36 ❋ 52 mm extra strength – Up to 144 dev available on a PSO........ 13.36 ❋ 54 mm, shaped – Up to 144 dev available on a PSO .................. 1.11 (2.60) ❋ 54 mm, shaped – Up to 144 dev available on a PSO ................ 13.36 (14.84) ❋ 56mm, shaped – Up to 144 dev available on a PSO ................... 1.11 (1.24) ❋ 56mm, shaped – Up to 144 dev available on a PSO ................. 13.36 (14.84) 144 144 12 144 Lifestyles Flared 12 Durex Confidence 144 Durex Confidence ✔ Marquis Supalite ✔ Marquis Protecta Lifestyles Flared

PAMIDRONATE DISODIUM – Special Authority see SA0091 – Hospital Pharmacy [HP3] ( subsidy) Inj 3 mg per ml, 5 ml ............................................................... 18.75 1 ✔ Pamisol Inj 3 mg per ml,10 ml .............................................................. 37.50 1 ✔ Pamisol Inj 6 mg per ml,10 ml .............................................................. 75.00 1 ✔ Pamisol DESMOPRESSIN ( subsidy) ▲ asal Spray 10 µ per dose – N Retail Pharmacy – Specialist ................................................ 29.94

85 86

6 ml OP

✔ Desmopressin-PH&T

CEFUROXIME AXETIL – Subsidy by endorsement ( subsidy) Only if prescribed for prophylaxis of endocarditis and the prescription is endorsed accordingly. Tab 250 mg ............................................................................ 29.40 50 ✔ Zinnat FLUCONAZOLE - Hospital Pharmacy [HP3]- Specialist ( subsidy) Cap 50 mg ................................................................................ 6.82 Cap 150 mg .............................................................................. 1.30 Cap 200 mg ............................................................................ 19.05 TERBINAFINE ( subsidy) Tab 250 mg ............................................................................ 25.50 NORFLOXACIN ( subsidy) Tabs 400 mg – Maximum of 6 tab per prescription; can be waived by endorsement – Retail Pharmacy – Specialist ................................................ 22.50 METOCLOPRAMIDE HYDROCHLORIDE ( subsidy) ❋ Inj 5 mg per ml, 2 ml – Up to 5 inj available on a PSO ............ 4.50 PERGOLIDE – Retail Pharmacy – Specialist ( subsidy) ▲ Tab 0.25 mg ........................................................................... 48.00 ▲ Tab 1 mg .............................................................................. 170.00 CALCIUM FOLINATE ( subsidy) Inj 50 mg – PCT – Hospital pharmacy [HP1] – Specialist ......... 24.50 PENTOSTATIN (DEOXYCOFORMYCIN) – PCT only – Specialist (Now CBS) Inj 10 mg ............................................................................. CBS 28 1 28 100 ✔ Pacific ✔ Pacific ✔ Pacific

90 96

✔ Apo-Terbinafine

100 5 100 100 5

✔ Arrow-Norfloxacin

113 115

✔ Pfizer

✔ Permax ✔ Permax ✔ Calcium Folinate Ebewe ✔ Nipent S29

126

131

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price - effective 1 July 2008 (continued)

148 SALBUTAMOL WITH IPRATROPIUM BROMIDE ( subsidy) Aerosol inhaler, 100 µg with ipratropium bromide, 20 µg per dose ................................................................... 13.50 BRIMONIDINE TARTRATE ( subsidy) ❋ Eye Drops 0.2%......................................................................... 7.93 GLYCEROL ( subsidy) ❋ Liquid – Only in combination.................................................... 19.80 (24.75) Only in extemporaneously compounded oral liquid preparations METHYL HYDROXYBENZOATE ( subsidy) Powder ................................................................................... 10.00 (18.45) METHYLCELLULOSE ( subsidy) Powder ................................................................................... 14.00 (17.72) SODIUM BICARBONATE ( subsidy) Powder BP - Only in combination............................................... 9.80 (11.99) (29.50) Only in extemporaneously compounded omeprazole suspension

200 dose OP ✔ Combivent 5 ml OP 2000 ml Midwest

153 161

✔ AFT

161

25 g PSM 100 g MidWest 500 g Biomed David Craig

161

162

178

AMINOACID FORMULA WITHOUT METHIONINE – Special Authority see SA0732 – Hospital pharmacy [HP3] ( subsidy) Powder ................................................................................. 461.94 500 g OP

✔ XMET Maxamum

178

AMINOACID FORMULA WITHOUT VALINE, LEUCINE AND ISOLEUCINE – Special Authority see SA0732 – Hospital pharmacy [HP3] ( subsidy) Powder ................................................................................. 300.54 500 g OP ✔ MSUD Maxamaid 437.22 ✔ MSUD Maxamum AMINOACID FORMULA WITH MINERALS WITHOUT PHENYLALANINE – Special Authority see SA0733 – Hospital pharmacy [HP3] ( subsidy) Powder ................................................................................... 58.44 250 g OP ✔ Metabolic Mineral Mixture

179

Effective 1 June 2008

54 LOSARTAN – Special Authority see SA0911 ( subsidy) ❋ Tab 12.5 mg ........................................................................... 17.40 ❋ Tab 50 mg ............................................................................. 23.10 30 30 ✔ Cozaar ✔ Cozaar

54 66

LOSARTAN WITH HYDROCHLOROTHIAZIDE – Special Authority see SA0911 ( subsidy) Tab 50 mg with hydrochlorothiazide 12.5 mg........................... 30.00 30 ✔ Hyzaar PARAFFIN ( subsidy) White soft – Only in combination ............................................. 20.20 2,500 g

✔ IPW

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price - effective 1 June 2008 (continued)

86 CEFUROXIME SODIUM – Hospital Pharmacy [HP3] ( subsidy) Inj 750 mg - Maximum of 1 inj per prescription; can be waived by endorsement ............................................ 10.71 Inj 1.5 g - Hospital pharmacy [HP3] – Specialist – Subsidy by endorsement ....................................................... 4.04 ASPIRIN ( subsidy) ❋ Tab dispersible 300 mg – Up to 30 tab available on a PSO ....... 21.50 (22.50) MORPHINE SULPHATE ( subsidy) a) Only on a controlled drug form b) No patient co-payment payable Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO .............. 4.50 Inj 30 mg per ml, 1 ml – Up to 5 inj available on a PSO .............. 4.98

5 1 1000

✔ Zinacef ✔ Zinacef

103

Ethics Aspirin

105

5 5

✔ Mayne ✔ Mayne

147

SALBUTAMOL ( subsidy) Aerosol inhaler, 100 µg per dose CFC free – Up to 1000 dose available on a PSO........................................................ 3.80 200 dose OP ✔ Salamol (6.00) Ventolin ACETIC ACID WITH 1, 2- PROPANEDIOL DIACETATE AND BENZETHONIUM ( subsidy) Ear drops 2% with 1, 2-Propanediol diacetate 3% and benzethonium chloride 0.02 % .............................................. 6.97 35 ml OP ✔ Vosol CARBOHYDRATE AND FAT SUPPLEMENT – Special Authority see SA0581 – Hospital pharmacy [HP3] ( subsidy) Powder (neutral) ..................................................................... 60.31 400 g OP

151

164

✔ Duocal Super Soluble Powder

166

FAT SUPPLEMENT – Special Authority see SA0899 – Hospital pharmacy [HP3] ( subsidy) Oil ........................................................................................... 28.73 250 ml OP ✔ Liquigen 30.00 500 ml OP ✔ MCT oil (Nutricia) FAT MODIFIED FEED – Special Authority see SA0615– Hospital pharmacy [HP3] ( subsidy) Powder ................................................................................... 60.48 400 g OP ✔ Monogen ENTERAL/ORAL FEED 1KCAL/ML – Special Authority see SA0607– Hospital pharmacy [HP3] ( subsidy) Powder ................................................................................... 78.97 400 g OP ✔ Generaid Plus ENTERAL/ORAL FEED 1KCAL/ML – Special Authority see SA0606 – Hospital pharmacy [HP3] ( subsidy) Liquid ...................................................................................... 54.00 400 g OP ✔ Kindergen ORAL ELEMENTAL FEED 0.8KCAL/ML – Special Authority see SA0592 – Hospital pharmacy [HP3] ( subsidy) Liquid (grapefruit) ..................................................................... 9.50 250 ml OP ✔ Elemental 028 Extra Liquid (pineapple & orange) ...................................................... 9.50 250 ml OP ✔ Elemental 028 Extra Liquid (summer fruit) ................................................................ 9.50 250 ml OP ✔ Elemental 028 Extra MULTIVITAMINS – Special Authority see SA0600– Hospital pharmacy [HP3] ( subsidy) Powder ................................................................................... 36.00 100 g OP ✔ Paediatric Seravit

168 169 169 171

179

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price - effective 1 June 2008 (continued)

180 LOW CALCIUM INFANT FORMULA – Special Authority see SA0601– Hospital pharmacy [HP3] ( subsidy) Powder ................................................................................... 44.40 400 g OP ✔ Locasol

Effective 1 May 2008

27 OMEPRAZOLE ( subsidy) ❋ Cap 10 mg ................................................................................ 2.00 ❋ Cap 20 mg ................................................................................ 2.85 ❋ Cap 40 mg ................................................................................ 3.35 46 60 DEXTROSE ( subsidy) ❋ Inj 50%, 10 ml – Up to 5 inj available on a PSO ........................ 22.75 GLYCERYL TRINITRATE ( subsidy) ❋ TDDS 5 mg ............................................................................. 16.56 ❋ TDDS 10 mg ........................................................................... 19.60 POVIDONE IODINE ( price) Skin preparation, povidone iodine 10% with 70% alcohol ............ 8.13 (18.63) 1.63 (6.04) SUNSCREENS, PROPRIETARY – Sunscreens by endorsement ( price) Crm........................................................................................... 1.74 (5.84) OESTRADIOL ( subsidy) ❋ Tab 2 mg .................................................................................. 4.12 (7.00) 28 28 28 ✔ Dr Reddy’s Omeprazole ✔ Dr Reddy’s Omeprazole ✔ Dr Reddy’s Omeprazole ✔ Biomed ✔ Nitroderm TTS ✔ Nitroderm TTS

5 30 30 500 ml

Orion 100 ml Orion 50 g OP Aquasun Oil Free Faces SPF 30+ 28 OP Estrofem ✔ AFT-Leflunomide ✔ AFT-Leflunomide

LEFLUNOMIDE – Special Authority see SA0635 – Retail Pharmacy ( subsidy) Tab 10 mg .............................................................................. 55.00 30 Tab 20 mg .............................................................................. 76.00 30

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to General Rules

Effective 1 June 2008

12 “Close Control” means the dispensing of a Community Pharmaceutical, in accordance with a Prescription, in quantities less than one 90 Day Lot (or, in the case of for oral contraceptives, less than one 180 Day Lot) for a Community Pharmaceutical referred to in Section F Part I, or in quantities less than a Monthly Lot for any other Community Pharmaceutical, where any of a), b) or c) apply. as applicable, where a) All of the following conditions are met: i) the Community Pharmaceutical is a tri-cyclic antidepressant, antipsychotic, benzodiazepine, a Class B Controlled Drug, or any other Community Pharmaceutical that has been prescribed for a patient who: 1A) is not a resident in a Penal Institution, Rest Home or Residential Disability Care Institution; and 2B) either of the following: i) in the opinion of the prescribing Practitioner Doctor, Midwife or Nurse Prescriber is: a. frail; or b. infirm; or c. unable to manage their medication without additional support; or d. intellectually impaired; or and e. requires close monitoring due to recent initiation onto, or dose change for, the Community Pharmaceutical (applicable to the patient’s first changed Prescription only); and f. requires that Community Pharmaceutical to be dispensed in a smaller quantity than that for which it is currently funded, or ii) the Community Pharmaceutical is any of the following: a. a tri-cyclic antidepressant; or b. an antipsychotic; or c. a benzodiazepine; or d. a Class B Controlled Drug; and ii) the prescribing Practitioner Doctor, Midwife or Nurse Prescriber has: A) endorsed each Community Pharmaceutical on the Prescription clearly with the words “close control” or “CC”; and B) initialled the endorsement in their the prescribers own handwriting; and C)specified the maximum quantity or period of supply to be dispensed at any one time. b) All of the following conditions are met: i) The Community Pharmaceutical is prescribed for a patient who is a resident in a Rest Home or Residential Disability Care Institution; and A)the quantity or period of supply to be dispensed at any one time is not less than 28 days’ supply; and B)the prescriber or pharmacist has written the name of the Rest Home or Residential Disability Care Institution on the prescription; and C)the prescriber or pharmacist has: 1) written on the Prescription the words “close control” or “CC” (this applies to all medicines prescribed on the prescription), and 2) initialled the endorsement/annotation in their own handwriting; and 3) specified the maximum quantity or period of supply to be dispensed at any one time. c) All of the following conditions are met: i) where PHARMAC has approved and notified pharmacists to annotate prescriptions for a specified Community Pharmaceutical(s) “Close Control” without prescriber endorsement for a specified time; and ii) the dispensing pharmacist has: A)clearly annotated each of the approved Community Pharmaceuticals that appear on the prescription with the words “close control” or “CC”; and B)initialled the annotation in their own handwriting; and C)specified the maximum quantity or period of supply to be dispensed at any one time, as specified by PHARMAC at the time of notification.

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to PSO

Effective 1 August 2008

CONDOMS 60 mm ...........................................144

Effective 1 July 2008

GLYCERYL TRINITRATE Tab 600 µg ....................................100 HYDROXOCOBALAMIN Inj 1 mg per ml, 1 ml ......................6

Effective 1 June 2008

CONDOMS 53 mm extra strength .....................144 55 mm ...........................................144 LEVONORGESTREL Tab 1.5 mg.....................................5

Effective 1 May 2008

CONDOMS 53 mm (chocolate) .........................144 55 mm (strawberry) .......................144

Changes to Sole Subsidised Supply

Effective 1 August 2008

For the list of new Sole Subsidised Supply products effective 1 August 2008 refer to the bold entries in the cumulative Sole Subsidised Supply table pages 8-13.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items

Effective 1 August 2008

52 177 PRAZOSIN HYDROCHLORIDE ❋ Tab 1 mg ................................................................................. 2.99 ❋ Tab 2 mg ................................................................................. 4.00 ❋ Tab 5 mg ................................................................................. 6.50 100 100 100 ✔ Hyprosin ✔ Hyprosin ✔ Hyprosin

GLUTEN FREE PASTA – Special Authority see SA0722– Hospital pharmacy [HP3] Rice and Maize Spaghetti .......................................................... 2.00 250 g OP (2.63)

Orgran

Effective 1 July 2008

28 31 INSULIN ISOPHANE ▲ Inj animal (pork) 100 u per ml ................................................. 25.26 10 ml OP ✔ Protaphane

GLUCOSE BLOOD DIAGNOSTIC TEST METER – Subsidy by endorsement a) Maximum of 1 meter per prescription b) A diagnostic blood glucose test meter is subsidised for patients who begin insulin or sulphonylurea therapy after 1 March 2005. Only one meter per patient. No further prescriptions will be subsidised. The prescription must be endorsed accordingly. Meter ...................................................................................... 19.00 1 ✔ Accu-Chek Advantage GLUCOSE DEHYDROGENASE The number of test strips available on a prescription is restricted to 50 unless: 1) Prescribed with insulin or a sulphonylurea but are on a different prescription and the prescription is endorsed accordingly; or 2) Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or 3) Prescribed for a pregnant woman with diabetes and endorsed accordingly. Blood/glucose test strips ........................................................ 22.00 50 test OP ✔ Accu-Chek Advantage MUCILAGINOUS LAXATIVES WITH STIMULANTS ❋ Dry ........................................................................................... 4.40 (12.00) METHOXSALEN – Retail pharmacy-Specialist Cap 10 mg .............................................................................. 11.66 VALACICLOVIR Tab 500 mg .......................................................................... 163.80 NELFINAVIR – Special Authority see SA0779 – Hospital pharmacy [HP1] Tab 250 mg ......................................................................... 600.00 Powder 50 mg per g ............................................................... 55.44 MORPHINE SULPHATE a) Only on a controlled drug form b) No patient co-payment payable Suppos 10 mg......................................................................... 11.08 Suppos 20 mg......................................................................... 20.31 250 g OP Granocol 25 30 270 144 g OP ✔ Oxsoralen

33 67 91 95

✔ Valtrex ✔ Viracept ✔ Viracept

105

12 12

✔ Martindale S29 ✔ Martindale S29

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items - effective 1 July 2008 (continued)

117 147 TRIFLUOPERAZINE HYDROCHLORIDE ‡ Oral liq 1 mg per ml ................................................................ 74.80 1,000 ml ✔ Stelazine

BUDESONIDE WITH EFORMOTEROL – Special Authority see SA0838– Retail pharmacy Aerosol inhaler 100 µg with eformoterol fumarate 6 µg ............ 55.00 120 dose OP ✔ Symbicort Rapihaler Aerosol inhaler 200 µg with eformoterol fumarate 6 µg ............ 60.00 120 dose OP ✔ Symbicort Rapihaler TERBUTALINE SULPHATE Inj 500 µg per ml, 1 ml ........................................................... 10.21 5 ✔ Bricanyl

147

Effective 1 June 2008

27 62 PANTOPRAZOLE ❋ Tab 20 mg ............................................................................... 2.24 (22.00) ❋ Tab 40 mg ............................................................................... 3.36 (28.00) ECONAZOLE NITRATE Crm 1% ..................................................................................... 1.00 (1.30) 28 Somac 28 Somac 15 g OP Ecreme

87 87 131

CLARITHROMYCIN – Maximum of 500 mg per prescription; can be waived by Special Authority see SA0657 Tab 250 mg ............................................................................. 7.75 14 ✔ Clarac ERYTHROMYCIN LACTOBIONATE Inj 1 g ....................................................................................... 6.50 MITOZANTRONE – PCT only – Specialist Inj 2 mg per ml, 10ml ........................................................... 330.00 1 1

✔ ERA

✔ Onkotrone

Effective 1 May 2008

47 WATER 1) On a prescription or Practitioner’s Supply Order only when on the same form as an injection listed in the Pharmaceutical Schedule requiring a solvent or diluent; or 2) On a bulk supply order; or 3) When used in the extemporaneous compounding of eye drops. Purified for inj 5 ml – Available on a PSO ................................... 9.31 50 ✔ AstraZeneca Purified for inj 10 ml – Available on a PSO ............................... 10.38 50 ✔ AstraZeneca RITONAVIR – Special Authority see SA0779 – Hospital pharmacy [HP1] Oral liq 80 mg per ml ............................................................ 277.28 Note: The 90 ml OP of Norvir will continue to be listed fully subsidised. NAPROXEN SODIUM ❋ Tab 275 mg ............................................................................. 5.00 240 ml OP ✔ Norvir

100

✔ Synflex

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items - effective 1 May 2008 (continued)

119 ALPRAZOLAM – Retail pharmacy-Specialist Month Restriction Tab 250 µg .............................................................................. 4.77 (8.11) ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 500 µg .............................................................................. 8.60 (16.26) ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 1 mg ............................................................................... 15.70 (32.51) ‡ Safety cap for extemporaneously compounded oral liquid preparations. SULPHACETAMIDE SODIUM ❋ Eye drops 10% ......................................................................... 3.60 ACETYLCYSTEINE – Hospital pharmacy [HP1]-Specialist Inj 200 mg per ml, 10 ml ...................................................... 137.06 (242.50)

100 Xanax 100 Xanax 100 Xanax

152 161

15 ml OP 10

✔ Acetopt

Parvolex

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted

Effective 1 September 2008

103 ASPIRIN ❋ Tab dispersible 300 mg – Up to 30 tab available on a PSO ....... 21.50 (22.50) 1000 Ethics Aspirin

Effective 1 October 2008

131 PACLITAXEL – PCT only – Specialist Inj 30 mg ............................................................................... 90.00 Inj 100 mg ........................................................................... 299.70 1 1 ✔ Taxol ✔ Taxol

Effective 1 November 2008

43 APROTININ Inj 10,000 µg per ml 50 ml ...................................................... 63.60 (73.40) VERAPAMIL HYDROCHLORIDE ❋ Tab 80 mg ............................................................................... 6.00 CEFUROXIME SODIUM Inj 750 mg – Maximum of 1 inj per prescription; can be waived by endorsement ............................................ 21.42 (56.47) Inj 1.5 g- Hospital pharmacy [HP3] – SpecialistSubsidy by endorsement ..................................................... 40.40 (123.55) 1 1 100

Trasylol ✔ Verpamil

58 86

10 Mayne 10 Mayne ✔ Norvir

RITONAVIR – Special Authority see SA0779 on page 93 – Hospital pharmacy [HP1] Cap 100 mg .......................................................................... 242.55 168 Note – the 84 pack size will continue to be listed fully subsidised

Effective 1 December 2008

30 73 TOLBUTAMIDE ❋ Tab 500 mg ............................................................................ 12.00 LEVONORGESTREL ❋ Tab 750 µg .............................................................................. 8.50 a) Maximum of 4 tab per prescription b Up to 10 tab available on a PSO CYPROTERONE ACETATE – Hospital pharmacy [HP3] – Specialist Inj 100 mg per ml, 3 ml ......................................................... 196.82 OESTRADIOL VALERATE ❋ Tab 1 mg .................................................................................. 4.12 100 2 ✔ Diatol ✔ Postinor-2

78 79

3 28

✔ Androcur Depot

✔ Progynova

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted - effective 1 December 2008 (continued)

102 ORPHENADRINE CITRATE Inj 30 mg per ml, 2 ml ............................................................... 9.60 (20.50) PROCHLORPERAZINE ❋ Suppos 5 mg............................................................................. 9.52 (18.13) 3 Norflex 5 Stemetil

114

168 168

DIABETIC ENTERAL FEED 1KCAL/ML – Special Authority see SA0594 – Hospital Pharmacy [HP3] Liquid ........................................................................................ 7.50 1,000 ml OP ✔ Glucerna RTH ORAL FEED 1KCAL / ML Liquid (vanilla)........................................................................... 1.88 250 ml OP ✔ Glucerna Note : Glucerna RTH and Glucerna replaced by Glucerna Select RTH and Glucerna See New Listings

Effective 1 January 2009

63 DIFLUCORTOLONE VALERATE Oint 0.1% .................................................................................. 8.97 (15.23) SALICYLIC ACID Powder – Only in combination ................................................. 15.00 (55.63) TENOXICAM ❋ Suppos 20 mg .......................................................................... 5.30 50 g OP Nerisone 500 g David Craig 10

99 173

✔ Tilcotil

ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA0702 – Hospital pharmacy [HP3] Liquid ........................................................................................ 3.50 500 ml OP ✔ Nutrison Energy Multi Fibre GLUTEN FREE PASTA – Special Authority see SA0722– Hospital pharmacy [HP3] Garlic and Parsley Spirals .......................................................... 2.00 250 g OP (2.63)

177

Orgran

179

AMINOACID FORMULA WITH MINERALS WITHOUT PHENYLALANINE – Special Authority see SA0733 – Hospital pharmacy [HP3] Powder ................................................................................... 45.06 250 g OP ✔ Aminogran Mineral Mix

Effective 1 February 2009

52 PRAZOSIN HYDROCHLORIDE ❋ Tab 0.5 mg ............................................................................... 9.50 100 ✔ Hyprosin

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted - effective 1 February 2009 (continued)

86 PYRANTEL EMBONATE Tab 125 mg .............................................................................. 5.31 (7.00) Tab 250 mg .............................................................................. 3.76 (4.95) METRONIDAZOLE Suppos 1 g ............................................................................. 33.31 NORTRIPTYLINE HYDROCHLORIDE Tab 25 mg .............................................................................. 34.90 METHOTREXATE Inj 100 mg per ml, 5 ml – PCT – Hospital pharmacy [HP1] – specialist .......................................................................... 18.00 KETOTIFEN ❋ Oral liq 1 mg per 5 ml ................................................................ 4.90 (5.90) 18 Combantrin 6 Combantrin 10 500 ✔ Flagyl

90 107 128

✔ Norpress

1 200 ml

✔ Methotrexate Ebewe

145

Asmafen

167

ORAL SUPPLEMENT 1KCAL/ML – Special Authority see SA0583 – Hospital Pharmacy [HP3] Powder (vanilla) ...................................................................... 11.50 900 g OP ✔ Fortisip Powder

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes to Part II

Effective 1 August 2008

ADALIMUMAB (new listing) Inj 40 mg per 0.8 ml prefilled pen ...............................HumiraPen

1,799.92

2 Oct-08 Oct-08 Oct-08 AFT AFT AFT

CEFOTAXIME (new listing) Inj 500 mg......................................Cefotaxime Sandoz 1.69 1 1% Inj 1 g.............................................Cefotaxime Sandoz 1.90 1 1% Inj 2 g.............................................Cefotaxime Sandoz 2.60 1 1% Note - AFT brand of cefotaxime inj, 1 g & 2 g will be delisted 1 October 2008. GLYCERYL TRINITRATE Tab 600 µg ....................................Lycinate IVERMECTIN (new listing) Tab 3 mg........................................Stromectol KETOCONAZOLE (new listing) Shampoo 2 % .................................Sebizole METHOTREXATE Inj 100 mg per ml, 5 ml ..................Methotrexate METRONIDAZOLE Suppos 1 g.....................................Flagyl 8.00 25.96 3.48 100 4 100 ml 1% 1% 1%

Sept-08 Oct-08 Oct-08

(B) (B) Ketopine Nizoral

18.00 33.31

1 10 1 1 1 1 1 1% 1% 1% 1% 1% Oct-08 Oct-08 Oct-08 Oct-08 Oct-08 Anzatax Taxol Anzatax Taxol (B) Anzatax Taxol Anzatax Taxol

PACLITAXEL (new listing) Inj 30 mg .......................................Paclitaxel Ebewe 37.95 Inj 100 mg......................................Paclitaxel Ebewe125.35 Inj 600 mg......................................Paclitaxel Ebewe724.50 PACLITAXEL ( price and addition of HSS) Inj 150 mg......................................Paclitaxel Ebewe188.03 Inj 300 mg......................................Paclitaxel Ebewe376.05

Note - The Taxol brand of paclitaxel inj 150 mg & 300 mg will be delisted from 1 October 2008.

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Index

Pharmaceuticals and brands A Abilify ................................................................ 14 ABM Hydroxocobalamin ..................................... 15 Acetic acid with 1, 2- propanediol diacetate and benzethonium ............................................ 29 Accu-Chek Advantage ........................................ 33 Acetopt .............................................................. 35 Acetylcysteine.................................................... 35 Actigall ........................................................ 19, 25 Adalimumab................................................. 14, 39 AFT-Leflunomide ................................................ 30 AFT-Pyrazinamide .............................................. 24 Alfacalcidol ........................................................ 19 Alpha tocopheryl acetate .................................... 19 Alprazolam ......................................................... 35 Aminoacid formula with minerals without phenylalanine ................................ 28, 37 Aminoacid formula without methionine ............... 28 Aminoacid formula without valine, leucine and isoleucine ................................................. 28 Aminogran Mineral Mix....................................... 37 Androcur Depot .................................................. 36 Apo-Gliclazide .................................................... 25 Apo-Terbinafine.................................................. 27 Aprotinin ............................................................ 36 Aquasun 30+ .................................................... 26 Aquasun Oil Free Faces SPF 30+ ....................... 26 Aquasun Oil Free Faces SPF 30+ Confidence ..... 30 Aquasun Sensitive SPF 30+ .............................. 26 Aripiprazole ........................................................ 14 Arrow-Norfloxacin .............................................. 27 Asmafen ............................................................ 38 Aspirin ......................................................... 29, 36 B Benzydamine hydrochloride................................ 19 Beta Cream ........................................................ 26 Betaferon ........................................................... 25 Betamethasone valerate ..................................... 26 Beta Ointment .................................................... 26 Bricanyl ............................................................. 34 Brimonidine tartrate ............................................ 28 Budesonide ........................................................ 18 Budesonide with eformoterol ........................ 15, 34 C Calcium ............................................................. 15 Calcium Sandoz ................................................. 15 Calcitriol ............................................................ 19 Calcitriol-AFT ..................................................... 19 Calcium folinate ................................................. 27 Calcium Folinate Ebewe...................................... 27 Calcium polystyrene sulphonate ......................... 19 Calcium Resonium ............................................. 19 Calsource .......................................................... 15 Carbohydrate ..................................................... 23 Carbohydrate and fat supplement ....................... 29 Cefotaxime......................................................... 39 Cefotaxime Sandoz ............................................ 39 Cefuroxime axetil................................................ 27 Cefuroxime sodium ................................ 25, 29, 36 Clarac ................................................................ 34 Clarithromycin.................................................... 34 Clomazol............................................................ 26 Clotrimazole ....................................................... 26 Combivent ......................................................... 28 Condoms ............................. 14, 16, 17, 25, 27, 32 Colofac .............................................................. 18 Combantrin ........................................................ 37 Cozaar ......................................................... 16, 28 Cyproterone acetate ........................................... 36 Cytotec .............................................................. 18 D Desmopressin .................................................... 27 Desmopressin-PH&T.......................................... 27 Dextrose ............................................................ 30 Diabetic enteral feed 1kcal/ml ...................... 16, 37 Diatol ................................................................. 36 Difflam ............................................................... 19 Diflucortolone valerate ........................................ 37 Dipentum ........................................................... 18 Dr Reddy’s Omeprazole................................ 15, 30 Duocal Super Soluble Powder ............................ 29 Durex Confidence ......................................... 25, 27 E Econazole nitrate ......................................... 25, 34 Ecreme .............................................................. 34 Efexor XR ........................................................... 17 Elemental 028 Extra ........................................... 29 Emulsifying ointment .......................................... 26 Enteral feed with fibre 1.5kcal/ml ........................ 37 Enteral/oral feed 1kcal/ml ................................... 29 Entocort CIR ...................................................... 18 ERA ................................................................... 34 Erythromycin lactobionate .................................. 34 Estrofem ............................................................ 30 Ethics Aspirin ............................................... 29, 36 F Fat modified feed................................................ 29 Fat supplement .................................................. 29 Ferrum H............................................................ 15 Flagyl ........................................................... 38, 39 Fluconazole ........................................................ 27 Fortisip Powder ............................................ 16, 38 G Gabapentin ........................................................ 21

Index

Pharmaceuticals and brands Generaid Plus..................................................... 29 Gliclazide ........................................................... 25 Glucerna ............................................................ 37 Glucerna RTH .................................................... 37 Glucerna Select .................................................. 16 Glucerna Select RTH .......................................... 16 Glucose blood diagnostic test meter ................... 33 Glucose dehydrogenase ..................................... 33 Gluten free bread mix ......................................... 25 Gluten free flour ................................................. 25 Gluten free pasta .................................... 15, 33, 37 Glycerol ............................................................. 28 Glyceryl trinitrate ........................ 15, 18, 30, 32, 39 Gold Knight .................................................. 16, 17 Granocol ............................................................ 33 H Hamilton Sunscreen ........................................... 26 Heparinised saline .............................................. 15 Horleys Bread Mix .............................................. 25 Horleys Flour...................................................... 25 HumiraPen ................................................... 14, 39 Hydrocortisone .................................................. 26 Hydroxocobalamin ....................................... 15, 32 Hyprosin ...................................................... 33, 37 Hyzaar ............................................................... 28 I Insulin syringes disposable with attached needle 17 Insulin isophane ................................................. 33 Insulin pen needles............................................. 16 Interferon beta-1-beta......................................... 25 Iron polymaltose ................................................ 15 Ivermectin .......................................................... 39 K Keppra ............................................................... 14 Ketoconazole ............................................... 14, 39 Ketotifen ............................................................ 38 Kindergen .......................................................... 29 L Lamotrigine........................................................ 16 Leflunomide ....................................................... 30 Levetiracetam .................................................... 14 Levonorgestrel ................................. 16, 20, 32, 36 Lifestyles Flared ........................................... 25, 27 Liquigen ............................................................. 29 Locasol.............................................................. 30 Logem ............................................................... 16 Losartan ................................................ 16, 20, 28 Losartan with hydrochlorothiazide ................ 20, 28 Low calcium infant formula ................................ 30 Lycinate ................................................. 15, 18, 39 M Marquis Black .................................................... 14 Marquis Conforma ............................................. 14 Marquis Protecta ................................................ 27 Marquis Selecta ................................................. 14 Marquis Sensolite .............................................. 14 Marquis Supalite ................................................ 27 Marquis Tantaliza ............................................... 14 Marquis Titillata.................................................. 14 Maxalt Melt ........................................................ 16 MCT oil (Nutricia) ............................................... 29 Metabolic Mineral Mixture................................... 28 Methylcellulose .................................................. 28 Methyl hydroxybenzoate ..................................... 28 Mebeverine hydrochloride .................................. 18 Methotrexate ................................................ 38, 39 Methotrexate Ebewe ........................................... 38 Methoxsalen ...................................................... 33 Metoclopramide hydrochloride ........................... 27 Metronidazole .............................................. 38, 39 Micelle E ............................................................ 19 Miconazole nitrate .............................................. 26 Misoprostol........................................................ 18 Mitozantrone ...................................................... 34 Monogen ........................................................... 29 Morphine sulphate........................................ 29, 33 MSUD Maxamaid ............................................... 28 MSUD Maxamum ............................................... 28 Mucilaginous laxatives with stimulants ............... 33 Multivitamins ..................................................... 29 N Nalcrom ............................................................. 18 Naproxen sodium ............................................... 34 Nelfinavir............................................................ 33 Nerisone ............................................................ 37 Nipent ................................................................ 27 Nitroderm TTS.................................................... 30 Norflex ............................................................... 37 Norfloxacin ........................................................ 27 Norpress ...................................................... 15, 38 Nortriptyline hydrochloride............................ 15, 38 Norvir .................................................... 17, 34, 36 Nutrison Energy Multi Fibre................................. 37 O Oestradiol .......................................................... 30 Oestradiol valerate........................................ 16, 36 Olsalazine .......................................................... 18 Omeprazole............................................ 15, 25, 30 Omezol .............................................................. 25 One-Alpha .......................................................... 19 Onkotrone .......................................................... 34

Index

Pharmaceuticals and brands Oracort .............................................................. 26 Oral elemental feed 0.8kcal/ml............................ 29 Oral feed 1kcal / ml ...................................... 16, 37 Oral supplement 1kcal/ml ............................. 16, 38 Orgran ................................................... 15, 33, 37 Orphenadrine citrate ........................................... 37 Oxsoralen........................................................... 33 P Paclitaxel ......................................... 14, 25, 36, 39 Paclitaxel Ebewe .................................... 14, 25, 39 Paediatric Seravite.............................................. 29 Pamidronate disodium ....................................... 27 Pamisol ............................................................. 27 Pantoprazole ...................................................... 34 Paracare Double Strength ................................... 15 Paracare Junior .................................................. 15 Paracetamol....................................................... 15 Paraffin .............................................................. 28 Parvolex ............................................................. 35 Pentostatin (deoxycoformycin) ........................... 27 Peptisoothe ........................................................ 18 Pergolide ........................................................... 27 Permax .............................................................. 27 Pevaryl Foaming Solution ................................... 25 Postinor-1.................................................... 16, 20 Postinor-2.......................................................... 36 Povidone iodine ................................................. 30 Prazosin hydrochloride ................................. 33, 37 Prochlorperazine ................................................ 37 Progynova ................................................... 16, 36 Protaphane ........................................................ 33 Pyrantel embonate ............................................. 38 Pyrazinamide ..................................................... 24 R Ranitidine hydrochloride ..................................... 18 Resonium-A ....................................................... 19 Respigen ........................................................... 16 Ritonavir ................................................ 17, 34, 36 Rizatriptan benzoate ........................................... 16 Rocaltrol solution ............................................... 19 S Salamol ............................................................. 29 Salbutamol................................................... 16, 29 Salbutamol with ipratropium bromide.................. 28 Salicylic acid ................................................ 26, 37 Sebizole ....................................................... 14, 39 Shield XL ........................................................... 14 Sodium bicarbonate ........................................... 28 Sodium cromoglycate ........................................ 18 Sodium polystyrene sulphonate .......................... 19 Somac ............................................................... 34 Stelazine ............................................................ 34 Stemetil ............................................................. 39 Stromectol ......................................................... 39 Sulphacetamide sodium ..................................... 35 Sulphur .............................................................. 26 Sunscreens, proprietary ............................... 26, 30 Symbicort Rapihaler ........................................... 34 Synflex............................................................... 34 T Taxol ................................................................. 36 Tenoxicam ......................................................... 37 Terbinafine ......................................................... 27 Terbutaline sulphate ........................................... 34 Tilcotil ................................................................ 37 Tolbutamide ....................................................... 36 Topiramate......................................................... 22 Trasylol.............................................................. 36 Triamcinolone acetonide .................................... 26 Trifluoperazine hydrochloride .............................. 34 U Ursodeoxycholic acid ................................... 19, 25 V Valaciclovir .................................................. 17, 33 Valtrex ......................................................... 17, 33 Vannair .............................................................. 15 Venlafaxine ........................................................ 17 Ventolin ............................................................. 29 Verapamil hydrochloride ..................................... 36 Verpamil ............................................................ 36 Vigabatrin .......................................................... 22 Viracept ............................................................. 33 Vosol ................................................................. 29 W Water ................................................................. 34 X Xanax................................................................. 35 XMET Maxamum ................................................ 28 Z Zinacef ............................................................... 29 Zinc and castor oil .............................................. 15 Zinnat ................................................................ 27 Ziprasidone ........................................................ 20

Pharmaceutical Management Agency Level 14, Cigna House, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz Freephone Information line (9am-5pm weekdays) 0800 66 00 50

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

Metadata

Title

Schedule Update - effective 1 August 2008

Abstract

Page 1

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.